// App-Quantinova.ai

235 : Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma

Researchers

Presenter

  • Fengmin Zhao

Principal Investigators

  • Michael E. Williams

  • Randy D. Gascoyne

  • John C. Krauss

  • David Cella

  • Sandra J. Horning

  • Brad S. Kahl

Medical Centers

  • Dana Farber Cancer Institute, MA

  • Department of Medical Oncology, BC Cancer Agency Center for Lymphoid Cancer, Vancouver, BC, Canada

Locations

  • United States

  • Canada

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Depression

  • Lymphomas

  • Anxiety

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved